Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949669015> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2949669015 endingPage "486" @default.
- W2949669015 startingPage "486" @default.
- W2949669015 abstract "Background: Rituximab is an anti-CD20 monoclonal antibody that has been approved by FDA in 1997 for treatment of B cell lymphomas. Most data about the effect of Rituximab on survival come from either randomized controlled trials or retrospectively from local centers’ experiences. Aims: The aim of this study was to report on the real-world experience in the United States for patients with B-cell lymphomas using data available in the SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program's database. SEER incorporates data from 18 cancer registries all over the United States and includes data dating back to 1973. These nationwide and historical data enabled the comparison between cases diagnosed 1983–1997 (15 years before Rituximab approval) and cases diagnosed 1998–2012 (15 years after Rituximab approval).Methods: Data were obtained using SEER∗Stat version 8.3.5 where (SEER 18 Regs Nov 2017 Submission) database was used as the main data source. B-cell Non-Hodgkin lymphoma cases diagnosed between 1983 and 2012 were included. Survival analyses were made using IBM SPSS version 25.0 and SEER∗Stat software. Comparison between groups was done using Log-rank test while relative survival was calculated using Ederer II method. Results: A total number of 230577 cases were included in the analysis. B-Cell lymphomas showed a median survival of 94 months (95% CI: 93–95) compared to 50 months (95% CI: 48.7–51.3) in the post and pre rituximab eras, respectively. Log rank test showed statstically significant difference in survival between the two groups (p < 0.001) (Figure1). This difference was consistent among all stage groups (Table 1). Summary/Conclusion: Rituximab's approval has led to a dramatic improvement in survival of patients with B-Cell lymphomas. Data from United States confirms that this improvement was consistent in all disease stages." @default.
- W2949669015 created "2019-06-27" @default.
- W2949669015 creator A5006445547 @default.
- W2949669015 creator A5014912122 @default.
- W2949669015 creator A5018452011 @default.
- W2949669015 creator A5026467222 @default.
- W2949669015 creator A5028833538 @default.
- W2949669015 creator A5030631799 @default.
- W2949669015 creator A5036866696 @default.
- W2949669015 creator A5066894243 @default.
- W2949669015 creator A5070455368 @default.
- W2949669015 creator A5073787373 @default.
- W2949669015 creator A5086593040 @default.
- W2949669015 creator A5088147072 @default.
- W2949669015 creator A5088820789 @default.
- W2949669015 creator A5091335418 @default.
- W2949669015 date "2019-06-01" @default.
- W2949669015 modified "2023-09-27" @default.
- W2949669015 title "PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA" @default.
- W2949669015 doi "https://doi.org/10.1097/01.hs9.0000562584.48238.c8" @default.
- W2949669015 hasPublicationYear "2019" @default.
- W2949669015 type Work @default.
- W2949669015 sameAs 2949669015 @default.
- W2949669015 citedByCount "4" @default.
- W2949669015 countsByYear W29496690152020 @default.
- W2949669015 countsByYear W29496690152021 @default.
- W2949669015 crossrefType "journal-article" @default.
- W2949669015 hasAuthorship W2949669015A5006445547 @default.
- W2949669015 hasAuthorship W2949669015A5014912122 @default.
- W2949669015 hasAuthorship W2949669015A5018452011 @default.
- W2949669015 hasAuthorship W2949669015A5026467222 @default.
- W2949669015 hasAuthorship W2949669015A5028833538 @default.
- W2949669015 hasAuthorship W2949669015A5030631799 @default.
- W2949669015 hasAuthorship W2949669015A5036866696 @default.
- W2949669015 hasAuthorship W2949669015A5066894243 @default.
- W2949669015 hasAuthorship W2949669015A5070455368 @default.
- W2949669015 hasAuthorship W2949669015A5073787373 @default.
- W2949669015 hasAuthorship W2949669015A5086593040 @default.
- W2949669015 hasAuthorship W2949669015A5088147072 @default.
- W2949669015 hasAuthorship W2949669015A5088820789 @default.
- W2949669015 hasAuthorship W2949669015A5091335418 @default.
- W2949669015 hasBestOaLocation W29496690151 @default.
- W2949669015 hasConcept C10515644 @default.
- W2949669015 hasConcept C107130276 @default.
- W2949669015 hasConcept C126322002 @default.
- W2949669015 hasConcept C143998085 @default.
- W2949669015 hasConcept C2777547418 @default.
- W2949669015 hasConcept C2778527826 @default.
- W2949669015 hasConcept C2779338263 @default.
- W2949669015 hasConcept C2779391198 @default.
- W2949669015 hasConcept C2780653079 @default.
- W2949669015 hasConcept C66339696 @default.
- W2949669015 hasConcept C71924100 @default.
- W2949669015 hasConceptScore W2949669015C10515644 @default.
- W2949669015 hasConceptScore W2949669015C107130276 @default.
- W2949669015 hasConceptScore W2949669015C126322002 @default.
- W2949669015 hasConceptScore W2949669015C143998085 @default.
- W2949669015 hasConceptScore W2949669015C2777547418 @default.
- W2949669015 hasConceptScore W2949669015C2778527826 @default.
- W2949669015 hasConceptScore W2949669015C2779338263 @default.
- W2949669015 hasConceptScore W2949669015C2779391198 @default.
- W2949669015 hasConceptScore W2949669015C2780653079 @default.
- W2949669015 hasConceptScore W2949669015C66339696 @default.
- W2949669015 hasConceptScore W2949669015C71924100 @default.
- W2949669015 hasIssue "S1" @default.
- W2949669015 hasLocation W29496690151 @default.
- W2949669015 hasLocation W29496690152 @default.
- W2949669015 hasOpenAccess W2949669015 @default.
- W2949669015 hasPrimaryLocation W29496690151 @default.
- W2949669015 hasRelatedWork W2088144470 @default.
- W2949669015 hasRelatedWork W2143803333 @default.
- W2949669015 hasRelatedWork W2471341727 @default.
- W2949669015 hasRelatedWork W2589928310 @default.
- W2949669015 hasRelatedWork W2589944840 @default.
- W2949669015 hasRelatedWork W2737200651 @default.
- W2949669015 hasRelatedWork W2892399610 @default.
- W2949669015 hasRelatedWork W2949669015 @default.
- W2949669015 hasRelatedWork W3017276462 @default.
- W2949669015 hasRelatedWork W4386283543 @default.
- W2949669015 hasVolume "3" @default.
- W2949669015 isParatext "false" @default.
- W2949669015 isRetracted "false" @default.
- W2949669015 magId "2949669015" @default.
- W2949669015 workType "article" @default.